Emergent Biosolutions Inc (EBS) Chairman Sells $1,631,061.75 in Stock

Emergent Biosolutions Inc (NYSE:EBS) Chairman Fuad El-Hibri sold 27,725 shares of the stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $58.83, for a total transaction of $1,631,061.75. Following the sale, the chairman now directly owns 1,478,306 shares of the company’s stock, valued at approximately $86,968,741.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Fuad El-Hibri also recently made the following trade(s):

Get Emergent Biosolutions alerts: On Tuesday, February 26th, Fuad El-Hibri sold 10,369 shares of Emergent Biosolutions stock. The stock was sold at an average price of $59.65, for a total transaction of $618,510.85.

Emergent Biosolutions stock opened at $59.51 on Friday. The firm has a market capitalization of $3.23 billion, a P/E ratio of 27.06, a price-to-earnings-growth ratio of 1.04 and a beta of 1.38. Emergent Biosolutions Inc has a 1-year low of $46.93 and a 1-year high of $73.89. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.14. The business had revenue of $270.70 million during the quarter, compared to the consensus estimate of $269.05 million. Emergent Biosolutions had a net margin of 8.02% and a return on equity of 12.89%. The firm’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 earnings per share. On average, research analysts anticipate that Emergent Biosolutions Inc will post 3.27 earnings per share for the current year.

Several brokerages have recently issued reports on EBS. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 24th. ValuEngine downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald set a $75.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research report on Thursday, December 13th. Cowen reissued a “hold” rating and set a $64.00 price objective on shares of Emergent Biosolutions in a research report on Tuesday, November 20th. Finally, Chardan Capital set a $71.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research report on Friday, February 22nd. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Emergent Biosolutions currently has an average rating of “Buy” and a consensus target price of $70.00.

Institutional investors have recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group grew its position in Emergent Biosolutions by 78.7% in the fourth quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 199 shares in the last quarter. Quantamental Technologies LLC bought a new position in Emergent Biosolutions in the fourth quarter valued at $29,000. Semmax Financial Advisors Inc. bought a new position in Emergent Biosolutions in the fourth quarter valued at $30,000. Bronfman E.L. Rothschild L.P. grew its position in Emergent Biosolutions by 1,108.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,112 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 1,020 shares in the last quarter. Finally, Clarus Wealth Advisors grew its position in Emergent Biosolutions by 1,518.0% in the fourth quarter. Clarus Wealth Advisors now owns 1,618 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,518 shares in the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4189644/emergent-biosolutions-inc-ebs-chairman-sells-1631061-75-in-stock.html.

About Emergent Biosolutions

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Recommended Story: Market Capitalization – What it Means for Investors